## Results and analysis of data

The results of the data analysis were divided into five main sections as the following:-

socio-demographic data as age, sex, job ......ECT table (1) Part I Part Π Medical characteristics of the study subjects, and common problems related to chemotherapy before educational program implementation among study subjects, after the implementation of the educational program, and after three months tables (3, 4, and 5) Part III Patient's knowledge about cancer, chemotherapy, side effects of chemotherapy, relaxation technique before, after, and after three months **tables** (6, 7) Part IV Patient Quality of life (4 domains) physical, psychological, social, and spiritual before, after one month, and after three months. Tables (8-23) Part V Karnfesky function activities before, after one month, and after three months. Table (24). Part VI Relation between patient's knowledge and others variables as age 'sex, level of education, and job before, after one month and after three months. Table (25) Part V Π Relation between patient's quality of life and others variables as age ' sex, level of education and job job before, after one month and after three months. **Table (26-30)** Part V III Correlation between patient's information Scores, quality of life scores,

karnofesky performance and some research variables **Table (31)** 

## Part I: Sociodemographic Characteristics

**Table (1):** percentage distribution of the study subjects according to their sociodemographic characteristics.

Variables	N=50	%
Sex		
Male	19	38
Female	31	62
Age		
18-44	33	66
45-59	13	26
≥60	4	8
Marital status		
- single	7	14
- married	37	74
- divorced	3	6
- widow	3	6
Level of education		
- illiteracy	22	44
- read& write/ primary	12	24
- secondary	9	18
- university	7	14
Job	_	
- employed	7	14
- unemployed	16	32
- student	1	2
- house wife	26	52
Job type	10	26
- technical	13	26
- practical	37	74
Job status after disease	2	6
- working the full time	3 29	6 58
- working some time		
- leave work	18	36
Family numbers	20	40
3 4.5	20 24	40 48
4.3 >5	6	12
Income	U	12
- enough	34	68
- not enough	16	32
- not chough	10	3∠

**Continue Table (1):** Percentage distribution of the study subjects according to their sociodemographic characteristics.

Variables	N=50	%
Care givers		
- spouse	32	64
- parents	3	6
- siblings	9	18
- children	3	6
- others	3	6
Place of treatment		
- health insurance	3	6
- free	44	88
- the work	1	2
- others	2	4
Is this free		
- enough	42	84
- not enough	8	16

Table 1 showed that more than half (62%) of study subject were female, and less than two thirds (66%) of subject were aged 18-44 years old, while three quarter (74%) were married, and less than half of them (44%) were illiterates, also half of them (52%) were house wife, and more than half (58%) were work some of time, and less than thirds (64%) were care givers are spouse, while the majority (88%) of the subject take the treatment free.

## **Part II: Medical data**

**Table (2):** Percentage distributions of medical data of the study subjects.

Variables	N=50	%
Type of cancer		
- Breast cancer	18	36
- Hodgkin's	12	24
- Gastrointestinal tract cancer	4	8
- lung cancer	6	12
- others	10	20
Duration of disease		
- 1-3 months	31	62
- 4-7 months	9	18
- ≥8 months	10	20
Number of chemotherapeutic cycles		
- 2-6 cycles	34	68
- 7- 10 cycls	1	2
- more than 10	15	30
Chemotherapeutic drugs		
- 5FU+endoxan	8	16
- 5FU+endoxan+ Epirubicin	10	20
- cisplatin+ Gemzar	11	22
- Taxol+ carboplatin	7	14
- Adriamycin+ bleomycin+ Velban+DIC	8	16
- endoxan+ adriamycin+ Oncovin+ prednison	6	12

This table illustrates medical data for subjects of study, as regard to cancer diagnosis, the higher percentage (36%) were treated for breast cancer, while less percentage (8%) were treated for gastrointestinal tract cancer. in relation to duration of disease more than half of the sample (62%) ranged from 1-3 months, while (18%) of subject ranged from 4-7 months. As regard to number of treatment cycle, the majority (68%) of subject received 2-6 treatment cycles, while only (30%) received more than 10 treatment cycle. Also the most frequently administered chemotherapeutic agent were cisplatin +Gemezar in (22%) of subject, while the least (12%) of subject received Endoxan + Adrimycin + oncovin + prednisone.